Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)
No Thumbnail Available
Date
2017-10
Authors
Buti, Maria
Stepanova, Tatjana
Celen, Mustafa K.
Flisiak, Robert
Ryder, Stephen D.
Streinu, Adrian Cercel
Flaherty, John F.
Gaggar, Anu
Suri, Vithika
Mo, Shuyuan
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
Description
Bu çalışma, 20-24, Ekim 2017 tarihlerinde Washington[Amerika]’da düzenlenen 68. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting Kongresi‘nde bildiri olarak sunulmuştur.
Keywords
Gastroenterology & hepatology
Citation
Buti, M. vd. (2017). ''Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)''. Hepatology, 66(Supplement 1), Special Issue, 488A-488A.